The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).
about
MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor.Advances in the cellular immunological pathogenesis of type 1 diabetesThe role of inflammation in intravenous immune globulin-mediated hemolysis.Circulating immune mediators are closely linked in adult-onset type 1 diabetes as well as in non-diabetic subjects.
P2860
The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial).
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@ast
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@en
type
label
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@ast
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@en
prefLabel
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@ast
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@en
P2093
P2860
P1433
P1476
The systemic immune network in ...... tor antagonist (DIATOR Trial).
@en
P2093
Christian Herder
DIATOR Study Group
Hubert Kolb
Kathrin Lückemeyer
Nanette C Schloot
Stephan Martin
Wolfgang Koenig
P2860
P304
P356
10.1371/JOURNAL.PONE.0072440
P407
P577
2013-08-26T00:00:00Z